Helix BioPharma to Present Clinical Trial Progress and NASDAQ Uplisting Plans at Investor Summit
Helix BioPharma will present its Phase Ib/II clinical study for non-small cell lung cancer treatment and planned NASDAQ uplisting at the Q3 2025 Investor Summit, highlighting strategic moves to advance oncology therapies and access global capital markets.
Helix BioPharma Corp., a clinical-stage oncology company, will present at the Q3 2025 Investor Summit Virtual on September 16, 2025. The company plans to discuss its ongoing preparation for a Phase Ib/Randomized Phase II clinical study of L-DOS47 in combination with pembrolizumab for first-line treatment of non-small cell lung cancer (NSCLC), as well as its planned uplisting to NASDAQ in Q1 2026. These milestones reflect Helix's strategy to accelerate development of oncology assets with potential to transform hard-to-treat cancers into manageable conditions while positioning the company for broader visibility and access to global capital markets.
The Investor Summit is an exclusive quarterly virtual event for investors specializing in small and microcap stocks, emphasizing undervalued companies with strong growth catalysts. Investors will have the opportunity to book one-on-one meetings with CEO Thomas Mehrling for direct insight into the company's vision and near-term growth strategy. The presentation will be webcast live at https://investorsummitgroup.com/presentor/q3-track-1-helix-biopharma-corp/ on September 16 at 2:30 PM ET.
Helix's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company also advances two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, a first-in-class oral gemcitabine prodrug with bioavailability comparable to IV administration. The NASDAQ uplisting planned for Q1 2026 represents a significant step in Helix's efforts to enhance its market presence and attract institutional investment.
Investor Summit Group, the event organizer, focuses on connecting high-quality small and microcap companies with institutional investors, family offices, and high-net-worth individuals. The quarterly summits combine company presentations, live Q&A sessions, and one-on-one meetings, offering curated opportunities for investors to discover emerging growth stories. More information about the organizer is available at https://www.investorsummitgroup.com.